MedTrace Logo

miR-200b & miR-21 in Diabetic Wounds

NCT02581098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2024-04-25

No results posted yet for this study

Summary

This study aims to determine if elevated wound-edge endothelial miR-200b is a barrier to wound healing in diabetic patients and also to determine if ex vivo supplementation of miR-21 mimic and recombinant MFG-E8 resolve inflammation in wound macrophages isolated from NPWT sponges from diabetic wounds. This study will enroll 124 (60 in the miR-200b arm and 64 in the miR21 arm) Diabetic Wound patients who have wound tissue oxygenation adequate to support wound healing and will be in the study for 14 weeks that includes 4 study visits.

Conditions

Interventions

OTHER

No interventions

No interventions

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Indiana University

    lead OTHER

Principal Investigators

  • Chandan K Sen, PhD · Indiana University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2023-06-26
Completion
2023-06-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581098 on ClinicalTrials.gov